These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35538760)

  • 1. [Mechanism of Triclosan in the Treatment of Nonalcoholic Fatty Liver Disease Based on Network Pharmacology].
    Zuo C; Sun DL; Zhao TH; Wang JJ; Zhang ZZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):253-261. PubMed ID: 35538760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice.
    Yang H; Wei D; Zhang Y; Jian W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(6):691-708. PubMed ID: 37859322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment.
    Sun CY; Yang LL; Zhao P; Yan PZ; Li J; Zhao DS
    Hereditas; 2022 Dec; 159(1):44. PubMed ID: 36451177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation.
    Yang R; Yang H; Jiang D; Xu L; Feng L; Xing Y
    PeerJ; 2022; 10():e14171. PubMed ID: 36389420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on the action mechanism of the Polygonum perfoliatum L. on non-alcoholic fatty liver disease, based on network pharmacology and experimental validation.
    Liu G; Yang L; Tang Y; Lin J; Wang F; Shen J; Chang B; Kong X
    J Ethnopharmacol; 2024 Jan; 319(Pt 3):117330. PubMed ID: 37863399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
    Wang X; Wang J; Ying C; Xing Y; Su X; Men K
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
    Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
    Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effect and mechanism of Hippophae rhamnoides L. triterpenoid acids on improving NAFLD based on network pharmacology and experimental validation in vivo and in vitro.
    Ren L; Wang R; Wang Y; Tie F; Dong Q; Wang H; Hu N
    J Ethnopharmacol; 2024 Dec; 335():118657. PubMed ID: 39127115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and verification of the active ingredients and potential targets of Erhuang Quzhi Granules on non-alcoholic fatty liver disease based on network pharmacology.
    Li S; Wu X; Ma Y; Zhang H; Chen W
    J Ethnopharmacol; 2023 Jul; 311():116435. PubMed ID: 37023836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAR
    Huang P; Yang L; Liu Y; Jiang Y; Li Y; Chen Z; Song H; Zheng P
    Evid Based Complement Alternat Med; 2022; 2022():1124901. PubMed ID: 35035496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation.
    Wang L; Zhi Y; Ye Y; Zhang M; Ma X; Tie H; Ma X; Zheng N; Xia W; Song Y
    Biomed Res Int; 2020; 2020():8829346. PubMed ID: 33415161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
    Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo.
    Liu W; Shang J; Deng Y; Han X; Chen Y; Wang S; Yang R; Dong F; Shang H
    J Ethnopharmacol; 2022 Sep; 295():115382. PubMed ID: 35577161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation.
    Mao D; Guo J; Yang K; Yang F; Peng J; Jia X; Luo Z; Liu L; Yang E; Tang R; Lan H; Zheng Q
    Biochem Biophys Res Commun; 2024 Nov; 734():150424. PubMed ID: 39083974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.